Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 79

1.

Evaluation of Cannabidiol in Animal Seizure Models by the Epilepsy Therapy Screening Program (ETSP).

Klein BD, Jacobson CA, Metcalf CS, Smith MD, Wilcox KS, Hampson AJ, Kehne JH.

Neurochem Res. 2017 Jul;42(7):1939-1948. doi: 10.1007/s11064-017-2287-8. Epub 2017 May 6.

PMID:
28478594
2.

The National Institute of Neurological Disorders and Stroke (NINDS) Epilepsy Therapy Screening Program (ETSP).

Kehne JH, Klein BD, Raeissi S, Sharma S.

Neurochem Res. 2017 Jul;42(7):1894-1903. doi: 10.1007/s11064-017-2275-z. Epub 2017 May 2. Review.

3.

The newly developed CRF1-receptor antagonists, NGD 98-2 and NGD 9002, suppress acute stress-induced stimulation of colonic motor function and visceral hypersensitivity in rats.

Million M, Zhao JF, Luckey A, Czimmer J, Maynard GD, Kehne J, Hoffman DC, Taché Y.

PLoS One. 2013 Sep 6;8(9):e73749. doi: 10.1371/journal.pone.0073749. eCollection 2013.

4.

Electrophysiological evidence for rapid 5-HT₁A autoreceptor inhibition by vilazodone, a 5-HT₁A receptor partial agonist and 5-HT reuptake inhibitor.

Ashby CR Jr, Kehne JH, Bartoszyk GD, Renda MJ, Athanasiou M, Pierz KA, Seyfried CA.

Eur J Pharmacol. 2013 Aug 15;714(1-3):359-65. doi: 10.1016/j.ejphar.2013.07.014. Epub 2013 Jul 16.

5.

The pharmacokinetics and pharmacodynamics of zaleplon delivered as a thermally generated aerosol in a single breath to volunteers.

Avram MJ, Spyker DA, Kehne JH, Cassella JV.

J Clin Pharmacol. 2013 Feb;53(2):140-50. doi: 10.1177/0091270012436886.

PMID:
23436259
6.

Targeting memory processes with drugs to prevent or cure PTSD.

Cain CK, Maynard GD, Kehne JH.

Expert Opin Investig Drugs. 2012 Sep;21(9):1323-50. doi: 10.1517/13543784.2012.704020. Epub 2012 Jul 27. Review.

7.

Rapid acute treatment of agitation in patients with bipolar I disorder: a multicenter, randomized, placebo-controlled clinical trial with inhaled loxapine.

Kwentus J, Riesenberg RA, Marandi M, Manning RA, Allen MH, Fishman RS, Spyker DA, Kehne JH, Cassella JV.

Bipolar Disord. 2012 Feb;14(1):31-40. doi: 10.1111/j.1399-5618.2011.00975.x.

PMID:
22329470
8.

Discovery of N-(1-ethylpropyl)-[3-methoxy-5-(2-methoxy-4-trifluoromethoxyphenyl)-6-methyl-pyrazin-2-yl]amine 59 (NGD 98-2): an orally active corticotropin releasing factor-1 (CRF-1) receptor antagonist.

Hodgetts KJ, Ge P, Yoon T, De Lombaert S, Brodbeck R, Gulianello M, Kieltyka A, Horvath RF, Kehne JH, Krause JE, Maynard GD, Hoffman D, Lee Y, Fung L, Doller D.

J Med Chem. 2011 Jun 23;54(12):4187-206. doi: 10.1021/jm200365y. Epub 2011 May 27.

PMID:
21618986
9.

Rapid acute treatment of agitation in individuals with schizophrenia: multicentre, randomised, placebo-controlled study of inhaled loxapine.

Lesem MD, Tran-Johnson TK, Riesenberg RA, Feifel D, Allen MH, Fishman R, Spyker DA, Kehne JH, Cassella JV.

Br J Psychiatry. 2011 Jan;198(1):51-8. doi: 10.1192/bjp.bp.110.081513.

PMID:
21200077
10.

Emergence of anti-conflict effects of zolpidem in rhesus monkeys following extended post-injection intervals.

Rowlett JK, Kehne JH, Sprenger KJ, Maynard GD.

Psychopharmacology (Berl). 2011 Apr;214(4):855-62. doi: 10.1007/s00213-010-2093-3. Epub 2010 Nov 20.

11.

Therapeutic utility of non-peptidic CRF1 receptor antagonists in anxiety, depression, and stress-related disorders: evidence from animal models.

Kehne JH, Cain CK.

Pharmacol Ther. 2010 Dec;128(3):460-87. doi: 10.1016/j.pharmthera.2010.08.011. Epub 2010 Sep 6. Review.

12.

The dopamine D(2) receptor partial agonist aplindore improves motor deficits in MPTP-treated common marmosets alone and combined with L-dopa.

Jackson MJ, Andree TH, Hansard M, Hoffman DC, Hurtt MR, Kehne JH, Pitler TA, Smith LA, Stack G, Jenner P.

J Neural Transm (Vienna). 2010 Jan;117(1):55-67. doi: 10.1007/s00702-009-0323-9. Epub 2009 Oct 7.

PMID:
19809864
13.

Retrograde effects of triazolam and zolpidem on sleep-dependent motor learning in humans.

Morgan PT, Kehne JH, Sprenger KJ, Malison RT.

J Sleep Res. 2010 Mar;19(1 Pt 2):157-64. doi: 10.1111/j.1365-2869.2009.00757.x. Epub 2009 Aug 13.

14.

D2 receptor partial agonists: treatment of CNS disorders of dopamine function.

Kehne JH, Andree TH, Heinrich JN.

Curr Top Med Chem. 2008;8(12):1068-88. Review.

PMID:
18691133
15.

2-Arylpyrimidines: novel CRF-1 receptor antagonists.

Yoon T, De Lombaert S, Brodbeck R, Gulianello M, Krause JE, Hutchison A, Horvath RF, Ge P, Kehne J, Hoffman D, Chandrasekhar J, Doller D, Hodgetts KJ.

Bioorg Med Chem Lett. 2008 Aug 15;18(16):4486-90. doi: 10.1016/j.bmcl.2008.07.063. Epub 2008 Jul 18.

PMID:
18672365
16.

The design, synthesis and structure-activity relationships of 1-aryl-4-aminoalkylisoquinolines: a novel series of CRF-1 receptor antagonists.

Yoon T, De Lombaert S, Brodbeck R, Gulianello M, Chandrasekhar J, Horvath RF, Ge P, Kershaw MT, Krause JE, Kehne J, Hoffman D, Doller D, Hodgetts KJ.

Bioorg Med Chem Lett. 2008 Feb 1;18(3):891-6. doi: 10.1016/j.bmcl.2007.12.050. Epub 2008 Jan 3.

PMID:
18180159
17.

The CRF1 receptor, a novel target for the treatment of depression, anxiety, and stress-related disorders.

Kehne JH.

CNS Neurol Disord Drug Targets. 2007 Jun;6(3):163-82. Review.

PMID:
17511614
18.

Depression.

Duman RS, Kehne JH.

CNS Neurol Disord Drug Targets. 2007 Jun;6(3):161-2. No abstract available.

PMID:
17511613
19.

Depression.

Duman RS, Kehne JH.

CNS Neurol Disord Drug Targets. 2007 Apr;6(2):85-6. No abstract available.

PMID:
17430146
20.

Inflammation-induced reduction of spontaneous activity by adjuvant: A novel model to study the effect of analgesics in rats.

Matson DJ, Broom DC, Carson SR, Baldassari J, Kehne J, Cortright DN.

J Pharmacol Exp Ther. 2007 Jan;320(1):194-201. Epub 2006 Oct 18.

PMID:
17050782
21.

Non-peptidic CRF1 receptor antagonists for the treatment of anxiety, depression and stress disorders.

Kehne J, De Lombaert S.

Curr Drug Targets CNS Neurol Disord. 2002 Oct;1(5):467-93. Review.

PMID:
12769601
22.

Effects of the CRF(1) receptor antagonist, CP 154,526, in the separation-induced vocalization anxiolytic test in rat pups.

Kehne JH, Coverdale S, McCloskey TC, Hoffman DC, Cassella JV.

Neuropharmacology. 2000 Jun 8;39(8):1357-67.

PMID:
10818252
23.

Mixed D2/5-HT2A antagonism of cocaine-induced facilitation of brain stimulation reward.

Tsibulsky VL, Grocki S, Dashevsky BA, Kehne JH, Schmidt CJ, Sorensen SM, Frank RA.

Pharmacol Biochem Behav. 1998 Feb;59(2):275-80.

PMID:
9476970
24.

Mixed D2/5-HT2 antagonism differentially affects apomorphine- and amphetamine-induced stereotyped behavior.

Feldman DJ, Frank RA, Kehne JH, Flannery R, Brown D, Soni S, Byrd G, Shah S.

Pharmacol Biochem Behav. 1997 Oct;58(2):565-72.

PMID:
9300620
25.

Pharmacological characterization of MDL 105,519, an NMDA receptor glycine site antagonist.

Baron BM, Harrison BL, Kehne JH, Schmidt CJ, van Giersbergen PL, White HS, Siegel BW, Senyah Y, McCloskey TC, Fadayel GM, Taylor VL, Murawsky MK, Nyce P, Salituro FG.

Eur J Pharmacol. 1997 Apr 4;323(2-3):181-92.

PMID:
9128837
26.

The peripheral NK-1/NK-2 receptor antagonist MDL 105,172A inhibits tachykinin-mediated respiratory effects in guinea-pigs.

Kudlacz EM, Knippenberg RW, Shatzer SA, Kehne JH, McCloskey TC, Burkholder TP.

J Auton Pharmacol. 1997 Apr;17(2):109-19.

PMID:
9234081
27.

Preclinical characterization of MDL 27,192 as a potential broad spectrum anticonvulsant agent with neuroprotective properties.

Kehne JH, Kane JM, Chaney SF, Hurst G, McCloskey TC, Petty MA, Senyah Y, Wolf HH, Zobrist R, White HS.

Epilepsy Res. 1997 Apr;27(1):41-54.

PMID:
9169290
28.

Cyclic nitrone free radical traps: isolation, identification, and synthesis of 3,3-dimethyl-3,4-dihydroisoquinolin-4-ol N-oxide, a metabolite with reduced side effects.

Thomas CE, Bernardelli P, Bowen SM, Chaney SF, Friedrich D, Janowick DA, Jones BK, Keeley FJ, Kehne JH, Ketteler B, Ohlweiler DF, Paquette LA, Robke DJ, Fevig TL.

J Med Chem. 1996 Dec 6;39(25):4997-5004.

PMID:
8960560
29.

Effects of the selective 5-HT2A receptor antagonist MDL 100,907 on MDMA-induced locomotor stimulation in rats.

Kehne JH, Ketteler HJ, McCloskey TC, Sullivan CK, Dudley MW, Schmidt CJ.

Neuropsychopharmacology. 1996 Aug;15(2):116-24.

30.

Purification of the CIC-0 chloride channel from Torpedo california electroplax identification of a phosphorylation site for cAMP-dependent protein kinase.

Kehne J, Weber-Schürholz S, Meyer HE, Schürholz T.

Biol Chem Hoppe Seyler. 1996 Jun;377(6):363-72.

PMID:
8839982
31.

Preclinical characterization of the potential of the putative atypical antipsychotic MDL 100,907 as a potent 5-HT2A antagonist with a favorable CNS safety profile.

Kehne JH, Baron BM, Carr AA, Chaney SF, Elands J, Feldman DJ, Frank RA, van Giersbergen PL, McCloskey TC, Johnson MP, McCarty DR, Poirot M, Senyah Y, Siegel BW, Widmaier C.

J Pharmacol Exp Ther. 1996 May;277(2):968-81.

PMID:
8627580
33.

5-HT modulation of auditory and visual sensorimotor gating: I. Effects of 5-HT releasers on sound and light prepulse inhibition in Wistar rats.

Kehne JH, Padich RA, McCloskey TC, Taylor VL, Schmidt CJ.

Psychopharmacology (Berl). 1996 Mar;124(1-2):95-106.

PMID:
8935804
34.

Reversal of amphetamine-induced behaviours by MDL 100,907, a selective 5-HT2A antagonist.

Moser PC, Moran PM, Frank RA, Kehne JH.

Behav Brain Res. 1996;73(1-2):163-7.

PMID:
8788496
35.

Mixed D2/5-HT2A antagonism of amphetamine-induced facilitation of brain stimulation reward.

Frank RA, Tsibulsky V, Grocki S, Dashevsky B, Kehne JH, Schmidt CJ, Sorensen SM.

Pharmacol Biochem Behav. 1995 Dec;52(4):799-804.

PMID:
8587922
36.

MDL 100,458 and MDL 102,288: two potent and selective glycine receptor antagonists with different functional profiles.

Kehne JH, Baron BM, Harrison BL, McCloskey TC, Palfreyman MG, Poirot M, Salituro FG, Siegel BW, Slone AL, Van Giersbergen PL, et al.

Eur J Pharmacol. 1995 Sep 15;284(1-2):109-18.

PMID:
8549613
37.

The role of 5-HT2A receptors in antipsychotic activity.

Schmidt CJ, Sorensen SM, Kehne JH, Carr AA, Palfreyman MG.

Life Sci. 1995;56(25):2209-22. Review.

PMID:
7791509
38.

5-Aryl-3-(alkylthio)-4H-1,2,4-triazoles as selective antagonists of strychnine-induced convulsions and potential antispastic agents.

Kane JM, Staeger MA, Dalton CR, Miller FP, Dudley MW, Ogden AM, Kehne JH, Ketteler HJ, McCloskey TC, Senyah Y, et al.

J Med Chem. 1994 Jan 7;37(1):125-32.

PMID:
8289185
39.

Contribution of serotonin neurotoxins to understanding psychiatric disorders: the role of 5-HT2 receptors in schizophrenia and antipsychotic activity.

Schmidt CJ, Kehne JH, Carr AA, Fadayel GM, Humphreys TM, Kettler HJ, McCloskey TC, Padich RA, Taylor VL, Sorensen SM.

Int Clin Psychopharmacol. 1993 Nov;8 Suppl 2:25-32. Review. No abstract available.

PMID:
7911139
40.

Characterization of the 5-HT2 receptor antagonist MDL 100907 as a putative atypical antipsychotic: behavioral, electrophysiological and neurochemical studies.

Sorensen SM, Kehne JH, Fadayel GM, Humphreys TM, Ketteler HJ, Sullivan CK, Taylor VL, Schmidt CJ.

J Pharmacol Exp Ther. 1993 Aug;266(2):684-91.

PMID:
8102646
41.

Electrophysiological, biochemical and behavioral evidence for 5-HT2 and 5-HT3 mediated control of dopaminergic function.

Palfreyman MG, Schmidt CJ, Sorensen SM, Dudley MW, Kehne JH, Moser P, Gittos MW, Carr AA.

Psychopharmacology (Berl). 1993;112(1 Suppl):S60-7.

PMID:
7831442
42.

MDL 27,531 reduces spontaneous hindlimb contractions in rats with chronic transections of the spinal cord.

Kehne JH, Ketteler HJ, Kane JM, McCloskey TC, Senyah Y, Palfreyman MG.

Neurosci Lett. 1992 Nov 23;147(1):101-5.

PMID:
1480315
43.

MDL 26,479: a potential cognition enhancer with benzodiazepine inverse agonist-like properties.

Miller JA, Dudley MW, Kehne JH, Sorensen SM, Kane JM.

Br J Pharmacol. 1992 Sep;107(1):78-86.

44.

MDL 27,531 selectively reverses strychnine-induced seizures in mice.

Kehne JH, Kane JM, Miller FP, Ketteler HJ, Braun DL, Senyah Y, Chaney SF, Abdallah A, Dudley MW, Ogden AM, et al.

Br J Pharmacol. 1992 Aug;106(4):910-6.

45.
46.

3-(2-Carboxyindol-3-yl)propionic acid-based antagonists of the N-methyl-D-aspartic acid receptor associated glycine binding site.

Salituro FG, Harrison BL, Baron BM, Nyce PL, Stewart KT, Kehne JH, White HS, McDonald IA.

J Med Chem. 1992 May 15;35(10):1791-9.

PMID:
1534125
47.

Synthesis and pharmacology of 3-aryl-5,6-dihydro-6-oxo-1(4H)-pyridazineacetic acid derivatives.

Kane JM, Huber EW, Miller FP, Kehne JH.

Pharmazie. 1992 Apr;47(4):249-51.

PMID:
1518880
48.

Effects of the serotonin releasers 3,4-methylenedioxymethamphetamine (MDMA), 4-chloroamphetamine (PCA) and fenfluramine on acoustic and tactile startle reflexes in rats.

Kehne JH, McCloskey TC, Taylor VL, Black CK, Fadayel GM, Schmidt CJ.

J Pharmacol Exp Ther. 1992 Jan;260(1):78-89.

PMID:
1731054
49.

NMDA receptor complex antagonists have potential anxiolytic effects as measured with separation-induced ultrasonic vocalizations.

Kehne JH, McCloskey TC, Baron BM, Chi EM, Harrison BL, Whitten JP, Palfreyman MG.

Eur J Pharmacol. 1991 Feb 14;193(3):283-92.

PMID:
1675993
50.

Effects of the phosphodiesterase inhibitor rolipram on the acoustic startle response in rats.

Kehne JH, Boulis NM, Davis M.

Psychopharmacology (Berl). 1991;105(1):27-36.

PMID:
1660609

Supplemental Content

Support Center